Last reviewed · How we verify
NCT04484948
Utility of Breath-holding Test in Systemic Sclerosis
NA trial testing scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT in Systemic Sclerosis in 120 participants. Completed in 31 May 2023.
29 January 2021
Quick facts
| Lead sponsor | Seoul National University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 120 |
| Start date | 12 August 2020 |
| Primary completion | 29 January 2021 |
| Estimated completion | 31 May 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- scleroderma health assessment questionnaire (SHAQ), BHT, and 6MWT
Conditions studied
- Systemic Sclerosis — all drugs for Systemic Sclerosis →
Sponsor
Seoul National University Hospital
Who can join
19 and older, any sex, with Systemic Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the utility of breath-holding test as a marker of pulmonary disease severity in patients with systemic sclerosis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Utility of the breath-holding test in patients with systemic sclerosis.
Yeo J, Kim JY, Kim MH, Park JW, et al · · 2022 · cited 2× · PMID 35040945 · DOI 10.1093/rheumatology/keac020 -
Poster abstracts
· 2024
Verify or expand the search:
- PubMed search for NCT04484948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Sclerosis
Currently open trials in the same condition.
- NCT07335562 — A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versu · Phase 3 · recruiting
- NCT06947473 — Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. · Phase 1, PHASE2 · recruiting
- NCT07047690 — A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis · Phase 2 · recruiting
- NCT07246096 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel · EARLY_PHASE1 · recruiting
- NCT07295847 — A Study of AZD0120 in Autoimmune Diseases · Phase 1 · recruiting
Other Seoul National University Hospital trials
Trials by the same sponsor.
- NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
- NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
- NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
- NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04484948 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
- Last refreshed: 2 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04484948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing